Claims for Patent: 9,296,745

Summary for Patent: 9,296,745

Title:	Diacylglycerol acyltransferase 2 inhibitors
Abstract:	Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Inventor(s):	Ahn; Kay (Lexington, MA), Boehm; Markus (Mansfield, MA), Cabral; Shawn (Groton, CT), Carpino; Philip A. (Newton, MA), Futatsugi; Kentaro (Quincy, MA), Hepworth; David (Concord, MA), Kung; Daniel W. (Salem, CT), Orr; Suvi (San Diego, CA), Wang; Jian (Belmont, MA)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	14/384,508
Patent Claims:	1. A compound of Formula (I) ##STR00245## wherein: A is CR.sup.6R.sup.7, O or S; B is a bond, oxetanyl, ##STR00246## wherein m is 0, 1 or 2; p is 1, 2, 3 or 4; C and D are each individually selected from N, CH, CF and C(CH.sub.3), wherein if C is N then D is CH, CF or C(CH.sub.3) and if D is N then C is CH, CF or C(CH.sub.3); R.sup.1 is --C(O)-heterocyclyl, --C(O)--NR.sup.4R.sup.5, or a heteroaryl, wherein said heterocyclyl or heteroaryl is optionally substituted with 1 or 2 substituents selected independently from (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkoxy, halo, hydroxy(C.sub.1-C.sub.4)alkyl, mono-N- or di-N,N--(C.sub.1-C.sub.4)alkylamino, mono-N- or di-N,N--(C.sub.3-C.sub.6)cycloalkylamino, heterocyclyl, hydroxyl and cyano; R.sup.2 is (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.3-C.sub.6)cycloalkoxy, aryl, aryloxy, heteroaryloxy, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, --C(O)-heterocyclyl, --C(O)--NR.sup.4R.sup.5, or --NR.sup.4--C(O)--R.sup.5, wherein alkyl, alkoxy, cycloalkyl, cycloalkoxy, aralkyl, heteroaralkyl, aryl, aryloxy, heteroaryloxy, heteroaryl, heterocyclyl are each optionally substituted with one, two or three substituents selected independently from (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.3-C.sub.6)cycloalkoxy, --C(O)--(C.sub.1-C.sub.4)alkyl, --C(O)--(C.sub.3-C.sub.6)cycloalkyl, halo, --C(O)--(C.sub.1-C.sub.4)alkoxy, --C(O)--(C.sub.3-C.sub.6)cycloalkoxy, mono-N- or di-N,N--(C.sub.1-C.sub.4)alkylamino, mono-N- or di-N,N--(C.sub.3-C.sub.6)cycloalkylamino, (C.sub.1-C.sub.4)alkylcarbonylamino, (C.sub.3-C.sub.6)cycloalkylcarbonylamino, (C.sub.1-C.sub.4)alkylcarbonyl-N--(C.sub.1-C.sub.4)alkylamino, (C.sub.1-C.sub.4)alkylcarbonyl-N--(C.sub.3-C.sub.6)cycloalkylamino, (C.sub.3-C.sub.6)cycloalkylcarbonyl-N--(C.sub.1-C.sub.4)alkylamino, (C.sub.3-C.sub.6)cycloalkylcarbonyl-N--(C.sub.3-C.sub.6)cycloalkylamino, aminocarbonyl, mono-N- or di-N,N--(C.sub.1-C.sub.4)alkylaminocarbonyl, mono-N- or di-N,N--(C.sub.3-C.sub.6)cycloaminocarbonyl, mono-N- or di-N,N--(C.sub.1-C.sub.4)alkylcarbonyl, mono-N- or di-N,N--(C.sub.3-C.sub.6)cycloalkylcarbonyl, mono-N- or di-N,N--(C.sub.1-C.sub.4)alkoxycarbonyl, mono-N- or di-N,N--(C.sub.3-C.sub.6)cycloalkoxycarbonyl, (C.sub.1-C.sub.4)alkylthio, (C.sub.3-C.sub.6)cycloalkylthio, aminosulfonyl, (C.sub.1-C.sub.4)alkylsulfinyl, (C.sub.1-C.sub.4)alkylsulfonyl, (C.sub.3-C.sub.6)cycloalkylsulfinyl, (C.sub.3-C.sub.6)cycloalkylsulfonyl, mono-N- or di-N,N--(C.sub.1-C.sub.4)alkylaminosulfonyl, mono-N- or di-N,N--(C.sub.3-C.sub.6)cycloalkylaminosulfonyl, (C.sub.1-C.sub.4)alkylsulfonylamino, (C.sub.3-C.sub.6)cycloalkylsulfonylamino, (C.sub.1-C.sub.4)alkylsulfonyl-N--(C.sub.1-C.sub.4)alkylamino, (C.sub.1-C.sub.4)alkylsulfonyl-N--(C.sub.3-C.sub.6)cycloalkylamino, (C.sub.3-C.sub.6)cycloalkylsulfonyl-N--(C.sub.1-C.sub.4)alkylamino, (C.sub.3-C.sub.6)cycloalkylsulfonyl-N--(C.sub.3-C.sub.6)cycloalkylamino, aryl, heteroaryl, heterocyclyl, oxo, carboxyl, amino, hydroxyl and cyano, wherein said alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy and cycloalkoxy are optionally substituted independently with one to nine fluoro, or 1, 2 or 3 substituents selected from halo, --C(O)--OH, --C(O)--(C.sub.1-C.sub.4)alkoxy, aminocarbonyl, mono-N- or di-N,N--(C.sub.1-C.sub.4)alkylcarbonyl, mono-N- or di-N,N--(C.sub.3-C.sub.6)cycloalkylcarbonyl, cyano, amino and hydroxyl; R.sup.3 is (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl, hydroxyl or fluoro, wherein said alkyl is optionally substituted with one to nine fluoros and said (C.sub.3-C.sub.6)cycloalkyl is optionally substituted with one to six fluoros; R.sup.4 and R.sup.5 are each independently selected from hydrogen, (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl, aryl, heteroaryl, aryloxy, heteroaryloxy, aralkyl, heteroaralkyl, heterocyclyl, (C.sub.1-C.sub.4)alkoxy, and (C.sub.3-C.sub.6)cycloalkoxy, wherein R.sup.4 and R.sup.5 are each optionally substituted with (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.3-C.sub.6)cycloalkoxy, halo or cyano, wherein each of said alkyl, cycloalkyl, alkoxy or cycloalkoxy is optionally substituted with one to nine fluoros; R.sup.6 and R.sup.7 are each independently hydrogen, (C.sub.1-C.sub.4)alkyl, fluoro, (C.sub.1-C.sub.4)alkoxy, hydroxyl or cyano, wherein said alkyl is optionally substituted with one to nine fluoros; R.sup.8 is selected from fluoro, methyl or trifluoromethyl; R.sup.9 and R.sup.10 are each independently selected from hydrogen, fluoro, (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl, aryl or heteroaryl, wherein said alkyl is optionally substituted with one to nine fluoros, and said cycloalkyl is optionally substituted with one to six fluoros, and said aryl and heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, methyl, ethyl, isopropyl, cyclopropyl, methylthio, methoxy, cyano, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, oxo and trifluoromethylthio; and n is 0, 1 or 2; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 2. The compound of claim 1 wherein R.sup.1 is --C(O)-heterocyclyl, --C(O)--NR.sup.4R.sup.5, pyridyl, 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolyl, 6,7-dihydro-5H-pyrrolo[1,2-c]imidazolyl, wherein R.sup.1 is optionally substituted with 1 or 2 substituents independently selected from fluoro, methyl, hydroxyl or --CH.sub.2OH; D is CH, N, or CF; B is a bond, oxetanyl or ##STR00247## wherein p is 1 or 2; R.sup.3 is fluoro or methyl; R.sup.6 and R.sup.7 are each independently hydrogen, fluoro or methyl; R.sup.8 is selected from fluoro or methyl; and R.sup.9 and R.sup.10 are each individually selected from hydrogen, fluoro, or methyl; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 3. The compound of claim 2 wherein R.sup.1 is --C(O)-heterocyclyl or --C(O)--NR.sup.4R.sup.5 wherein said heterocyclyl is optionally substituted with 1 or 2 substituents independently selected from fluoro and methyl; B is a bond, ##STR00248## wherein p is 1 or 2; R.sup.2 is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridiazinyl, pyrimidinyl, pyrazinyl, pyridin-2(1H)-onyl, pyridazin-2(1H)-onyl, pyrimidin-2(1H)-onyl, pyrazin-2(1H)-onyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, 2H-benzo[b][1,4]oxazin-3(4H)-onyl, 2,3-dihydro-1H-indenyl, 1,2,3,4-tetrahydronaphthalenyl, 5,6,7,8-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 6,7-dihydro-5H-cyclopenta[b]pyridinyl, 6,7-dihydro-5H-cyclopenta[c]pyridinyl, 1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 2,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, 6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydro-1H-indazolyl, 4,5,6,7-tetrahydro-2H-indazolyl, phenyloxy, pyridinyloxy, benzyl, pyridinyl-(CH.sub.2)--, pyrazolyl-(CH.sub.2)--, cyclopropyl, and cyclobutyl; wherein said R.sup.2 is optionally substituted with 1, 2 or 3 substituents independently selected from (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkoxy, cyclopropyl, halo, hydroxyl, amino, dimethylamino, methylamino, cyclopropylamino, aminocarbonyl, methylaminocarbonyl, (C.sub.1-C.sub.4)alkylthio, (C.sub.3-C.sub.6)cycloalkylthio, aminosulfonyl, methylaminosulfonyl, phenyl, and heteroaryl wherein heteroaryl is selected from furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridiazinyl, pyrimidinyl, pyrazinyl, pyridin-2(1H)-onyl, pyridazin-2(1H)-onyl, pyrimidin-2(1H)-only, pyrazin-2(1H)-onyl, oxetanyl, azetidinyl, and pyrrolidinyl, wherein said alkyl, cyclopropyl, azetidinyl, pyrrolidinyl, alkoxy and cycloalkoxy are optionally substituted with oxo, cyano, or up to three fluoro or hydroxyl, and said phenyl or heteroaryl is optionally substituted independently with up to three groups selected from halo, methyl, trifluoromethyl, difluoromethyl, methoxy, trifluoromethoxy, difluoromethoxy, cyano, cyclopropryl, methylthio, oxo and trifluoromethylthio; and R.sup.9 and R.sup.10 are each individually selected from hydrogen and methyl; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 4. The compound of claim 3 wherein R.sup.1 is --C(O)-heterocyclyl or --C(O)--NR.sup.4R.sup.5 wherein said heterocyclyl is selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, azetidinyl, piperidinyl and morpholinyl and said heterocyclyl is optionally substituted with 1 or 2 substituents independently selected from fluoro and methyl; C is CH, N or CF; A is CH.sub.2 or O; R.sup.2 is phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridiazinyl, pyrimidinyl, pyrazinyl, pyridin-2(1H)-onyl, pyridazin-2(1H)-onyl, pyrimidin-2(1H)-onyl, pyrazin-2(1H)-onyl, phenyloxy, pyridinyloxy, benzyl, pyridinyl-(CH.sub.2)-- or pyrazolyl-(CH.sub.2)--, wherein R.sup.2 is optionally substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, methyl, ethyl, isopropyl, cyclopropyl, hydroxyl, amino, methylthio, methoxy, cyano, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, oxo and trifluoromethylthio; R.sup.4 is hydrogen or methyl; R.sup.5 is hydrogen or methyl; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 5. The compound of claim 4 wherein R.sup.1 is --C(O)-heterocyclyl, wherein said heterocyclyl is selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, 3,3-difluoroazetidinyl, 3,3-difluoropyrrolidinyl and morpholinyl; B is ##STR00249## wherein p is 1 or 2; and R.sup.2 is phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridiazinyl, pyrimidinyl, pyrazinyl, phenyloxy, pyridinyloxy, benzyl, pyridinyl-(CH.sub.2)--, or pyrazolyl-(CH.sub.2)--; wherein R.sup.2 is optionally substituted with 1, 2 or 3 substituents selected from independently fluoro, chloro, methyl, ethyl, isopropyl, cyclopropyl, methylthio, methoxy, cyano, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, oxo and trifluoromethylthio; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 6. The compound of claim 5 wherein R.sup.2 is N-linked pyrazolyl optionally substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, methyl, ethyl, isopropyl, cyclopropyl, hydroxyl, amino, methylthio, methoxy, cyano, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy and trifluoromethylthio or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 7. The compound of claim 6 wherein R.sup.1 is ##STR00250## C is CH or CF; A is CH.sub.2; n is 0; and R.sup.2 is N-linked pyrazolyl substituted at the 4 position with fluoro or chloro; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 8. A compound selected from the group consisting of: (1-(2-(1-(4-fluoro-1H-pyrazol-1-yl)cyclopropyl)-3H-imidazo[4,5-b]pyridin-- 5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone; (1-(8-(1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl)-9H-purin-2-yl)piperidin-3- -yl)(pyrrolidin-1-yl)methanone; (1-(2-(1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl)-3H-imidazo[4,5-b]pyridin-- 5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone; (1-(2-(2-(4-chloro-1H-pyrazol-1-yl)propan-2-yl)-3H-imidazo[4,5-b]pyridin-- 5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone; (1-{2-[1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl]-3H-imidazo[4,5-b]pyridin-- 5-yl}(2,2,6,6-.sup.2H.sub.4)piperidin-3-yl](pyrrolidin-1-yl)methanone; (1-(2-((R)-1-(4-fluoro-1H-pyrazol-1-yl)ethyl)-3H-imidazo[4,5-b]pyridin-5-- yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone; (1-(2-((S)-1-(4-fluoro-1H-pyrazol-1-yl)ethyl)-3H-imidazo[4,5-b]pyridin-5-- yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone; (1-(2-((S)-1-(4-chloro-1H-pyrazol-1-yl)ethyl)-3H-imidazo[4,5-b]pyridin-5-- yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone; (1-(2-((R)-1-(4-chloro-1H-pyrazol-1-yl)ethyl)-3H-imidazo[4,5-b]pyridin-5-- yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone; (1-(8-((S)-1-(4-chloro-1H-pyrazol-1-yl)ethyl)-9H-purin-2-yl)piperidin-3-y- l)(pyrrolidin-1-yl)methanone; (1-(8-((R)-1-(4-chloro-1H-pyrazol-1-yl)ethyl)-9H-purin-2-yl)piperidin-3-y- l)(pyrrolidin-1-yl)methanone; and (1-(8-(1-(4-fluoro-1H-pyrazol-1-yl)cyclopropyl)-9H-purin-2-yl)piperidin-3- -yl)(pyrrolidin-1-yl)methanone; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 9. A compound selected from the group consisting of: ((R)-1-(2-((S)-1-(4-Chloro-1H-pyrazol-1-yl)ethyl)-3H-imidazo[4,5-b]pyridi- n-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone, ((R)-1-(2-((R)-1-(4-Chloro-1H-pyrazol-1-yl)ethyl)-3H-imidazo[4,5-b]pyridi- n-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone, ((S)-1-(2-((S)-1-(4-Chloro-1H-pyrazol-1-yl)ethyl)-3H-imidazo[4,5-b]pyridi- n-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone, and ((S)-1-(2-((R)-1-(4-Chloro-1H-pyrazol-1-yl)ethyl)-3H-imidazo[4,5-b]pyridi- n-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone, or a mixture of thereof; or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 10. A compound selected from the group consisting of: (R)-(1-(2-(1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl)-3H-imidazo[4,5-b]pyri- din-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone, and (S)-(1-(2-(1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl)-3H-imidazo[4,5-b]pyri- din-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone, or a mixture of thereof; or tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 11. The compound having the structure ##STR00251## or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 12. The compound having the structure ##STR00252## or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer. 13. A pharmaceutical composition comprising a compound according to claim 1 or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer, present in a therapeutically effective amount, in admixture with at least one pharmaceutically acceptable excipient. 14. The composition of claim 13 further comprising at least one additional pharmaceutical agent selected from the group consisting of an anti-obesity agent, an anti-diabetic agent, and a cholesterol/lipid modulating agent. 15. The composition of claim 14 wherein said anti-obesity agent is selected from the group consisting of dirlotapide, mitratapide, implitapide, R56918, CCKa agonists, 5HT2c agonists, MCR4 agonist, lipase inhibitor, PYY.sub.3-36, opioid antagonists, the combination of naltrexone with buproprion, oleoyl-estrone, obinepitide, pramlintide, tesofensine, leptin, liraglutide, bromocriptine, orlistat, exenatide, AOD-9604 and sibutramine. 16. The composition of claim 14 wherein said anti-diabetic agent is selected from the group consisting of an acetyl-CoA carboxylase-inhibitor, a diacylglycerol O-acyltransferase 1 inhibitor, AZD7687, LCQ908, monoacylglycerol O-acyltransferase inhibitors, a phosphodiesterase-10 inhibitor, an AMPK activator, a sulfonylurea, a meglitinide, an .alpha.-amylase inhibitor, an .alpha.-glucoside hydrolase inhibitor, an .alpha.-glucosidase inhibitor, a PPAR.gamma. agonist, a PPAR .alpha./.gamma. agonist a biguanide, liraglutide, albiglutide, exenatide, lixisenatide, dulaglutide, semaglutide, NN-9924, TTP-054, a protein tyrosine phosphatase-1B inhibitor, SIRT-1 activator, a dipeptidyl peptidease IV inhibitor, an insulin secreatagogue, a fatty acid oxidation inhibitor, an A2 antagonist, a c-jun amino-terminal kinase inhibitor, glucokinase activators, insulin, an insulin mimetic, a glycogen phosphorylase inhibitor, a VPAC2 receptor agonist, SGLT2 inhibitors, a glucagon receptor modulator, GPR119 modulators, FGF21 derivatives or analogs, TGR5 receptor modulators, GPR40 agonists, GPR120 modulators, high affinity nicotinic acid receptor activators, SGLT1 inhibitors, inhibitors or modulators of carnitine palmitoyl transferase enzymes, inhibitors of fructose 1,6-diphosphatase, inhibitors of aldose reductase, mineralocorticoid receptor inhibitors, inhibitors of TORC2, inhibitors of CCR2 or CCR5, inhibitors of PKC isoforms, inhibitors of fatty acid synthetase, inhibitors of serine palmitoyl transferase, modulators of GPR81, GPR39, GPR43, GPR41, GPR105, Kv1.3, retinol binding protein 4, glucocorticoid receptor, somatostain, inhibitors or modulators of PDHK2 or PDHK4, inhibitors of MAP4K4, modulators of IL1 family, and modulators of RXRalpha. 17. The composition of claim 14 wherein said cholesterol/lipid modulating agent is selected from the group consisting of HMG-CoA reductase inhibitors; squalene synthetase inhibitors; fibrates; bile acid sequestrants; ACAT inhibitors; MTP inhibitors; lipooxygenase inhibitors; cholesterol absorption inhibitors; PCSK9 modulators and cholesteryl ester transfer protein inhibitors.

Details for Patent 9,296,745

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014		2032-04-06
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/18/2014		2032-04-06
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/04/2020		2032-04-06
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	07/27/2016		2032-04-06